Table 1.
Patient Characteristics
| Gender | Diabetes Mellitus | ||||
|---|---|---|---|---|---|
| Age (y), | Duration (y), | HbA1c (mmol/mol), | |||
| Cohort | mean ± SD | Female, n (%) | Male, n (%) | mean ± SD | mean ± SD |
| Screening cohort | |||||
| Controls (n = 10) | 66.0 ± 5.2 | 5 (50) | 5 (50) | — | — |
| PDR (n = 10) | 64.7 ± 6.1 | 5 (50) | 5 (50) | 26.7 ± 14.6 | 96.3 ± 22.6 |
| P | 0.614 | 1.000 | |||
| Confirmation cohort | |||||
| Controls (n = 17) | 71.1 ± 3.9 | 12 (71) | 5 (29) | — | — |
| PDR (n = 11) | 69.1 ± 9.0 | 4 (36) | 7 (64) | 20.1 ± 7.2 | 74.9 ± 10.9 |
| P | 0.417 | 0.079 | |||
| Anti-VEGF cohort | |||||
| Untreated PDR (n = 16) | 59.1 ± 13.4 | 8 (50) | 8 (50) | 21.7 ± 10.0 | 78.2 ± 20.8 |
| Treated PDR (n = 17) | 50.6 ± 13.3 | 6 (35) | 11 (65) | 22.5 ± 9.2 | 79.0 ± 22.0 |
| P | 0.076 | 0.409 | 0.817 | 0.918 | |
| Bevacizumab + ranibizumab (n = 11)a | 47.1 ± 10.6 | 4 (36) | 7 (64) | 19.5 ± 7.4 | 84.7 ± 20.0 |
| Aflibercept (n = 6) | 57.0 ± 16.3 | 2 (33) | 4 (67) | 27.8 ± 10.6 | 69.5 ± 23.7 |
| P | 0.149 | 0.908 | 0.076 | 0.190 | |
P < 0.05 was considered to be statistically significant.
a
This group includes 10 patients pretreated with bevacizumab and one patient pretreated with ranibizumab.